歡迎光臨源葉生物,登錄 | 注冊(cè) |
當(dāng)前位置: 首頁(yè) > 小分子抑制劑 > CytoskeletalSignaling > AZD-26

瀏覽歷史

S87881

AZD-26

源葉(MedMol) ≥98%
  • 英文名:
  • AZD-26
  • 別名:
  • 6-[4-(1-氨基環(huán)丁基)苯基]-5-苯基-3-吡啶甲酰胺
  • CAS號(hào):
  • 1357158-81-6
  • 分子式:
  • C22H21N3O
  • 分子量:
  • 343.42164
品牌貨號(hào)產(chǎn)品規(guī)格價(jià)格(RMB) 庫(kù)存(上海) 北京 武漢 南京 數(shù)量計(jì)量單位 加入購(gòu)物車...
源葉(MedMol) S87881-1mg ≥98% ¥900.00元 10 - - - EA 加入購(gòu)物車
源葉(MedMol) S87881-5mg ≥98% ¥1900.00元 7 - - - EA 加入購(gòu)物車
源葉(MedMol) S87881-10mg ≥98% ¥3700.00元 1 - - - EA 加入購(gòu)物車
源葉(MedMol) S87881-25mg ≥98% ¥5900.00元 3 - - - EA 加入購(gòu)物車
大包裝詢價(jià)

提交您的電話號(hào)碼并同意《個(gè)人信息授權(quán)與保護(hù)申明》,到貨后將短信提示。
提交

產(chǎn)品介紹

參考文獻(xiàn)

質(zhì)檢證書(COA)

摩爾濃度計(jì)算器

相關(guān)產(chǎn)品

  • 產(chǎn)品描述: AKT-IN-1 is an allosteric AKT inhibitor with an IC50 of 1.042 μM
  • 靶點(diǎn): IC50: 1.042 μM (AKT);Akt
  • 體外研究:
    AKT-IN-1 is able to potently inhibit phosphorylation of AKT in cells at both Thr308 and Ser473, with IC50s of 0.422 and 0.322 μM, respectively. AKT-IN-1 inhibits the phosphorylation of ribosomal protein S6, a downstream effector of the PI3K-AKT pathway. AKT-IN-1 potently inhibits the phosphorylation of PRAS40.
  • 體內(nèi)研究:
    The effects of AKT-IN-1 (Compound 26) in vivo are characterized by measuring the pharmacodynamic activity of AKT-IN-1 in a BT474c breast adenocarcinoma xenograft model. Following acute doses of 100 and 200 mg/kg, AKT-IN-1 potently inhibits the phosphorylation of its downstream substrate GSK3β as well as the phosphorylation of AKT (Ser473), with a potency consistent with its pharmacokinetic profile. The in vivo activity of AKT-IN-1 is further characterized by measuring the effects on the growth of tumor cell xenografts. Continuous (daily) oral dosing of AKT-IN-1 (100 and 200 mg/kg) to nude mice bearing BT474c breast adenocarcinoma xenografts results in inhibition of tumor growth in a dose-dependent manner. When dosed at 200 mg/kg daily, AKT-IN-1 causes significant tumor growth inhibition.
  • 參考文獻(xiàn):
    1: Kettle JG, Brown S, Crafter C, Davies BR, Dudley P, Fairley G, Faulder P, Fillery S, Greenwood H, Hawkins J, James M, Johnson K, Lane CD, Pass M, Pink JH, Plant H, Cosulich SC. Diverse heterocyclic scaffolds as allosteric inhibitors of AKT. J Med Chem. 2012 Feb 9;55(3):1261-73. doi: 10.1021/jm201394e. Epub 2012 Jan 27. PubMed PMID: 22248236.
  • 溶解性: Soluble  in  DMSO
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 2.912 ml 14.559 ml 29.119 ml
    5 mM 0.582 ml 2.912 ml 5.824 ml
    10 mM 0.291 ml 1.456 ml 2.912 ml
    50 mM 0.058 ml 0.291 ml 0.582 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
  • 產(chǎn)品描述: AKT-IN-1 is an allosteric AKT inhibitor with an IC50 of 1.042 μM
  • 靶點(diǎn): IC50: 1.042 μM (AKT);Akt
  • 體外研究:
    AKT-IN-1 is able to potently inhibit phosphorylation of AKT in cells at both Thr308 and Ser473, with IC50s of 0.422 and 0.322 μM, respectively. AKT-IN-1 inhibits the phosphorylation of ribosomal protein S6, a downstream effector of the PI3K-AKT pathway. AKT-IN-1 potently inhibits the phosphorylation of PRAS40.
  • 體內(nèi)研究:
    The effects of AKT-IN-1 (Compound 26) in vivo are characterized by measuring the pharmacodynamic activity of AKT-IN-1 in a BT474c breast adenocarcinoma xenograft model. Following acute doses of 100 and 200 mg/kg, AKT-IN-1 potently inhibits the phosphorylation of its downstream substrate GSK3β as well as the phosphorylation of AKT (Ser473), with a potency consistent with its pharmacokinetic profile. The in vivo activity of AKT-IN-1 is further characterized by measuring the effects on the growth of tumor cell xenografts. Continuous (daily) oral dosing of AKT-IN-1 (100 and 200 mg/kg) to nude mice bearing BT474c breast adenocarcinoma xenografts results in inhibition of tumor growth in a dose-dependent manner. When dosed at 200 mg/kg daily, AKT-IN-1 causes significant tumor growth inhibition.
  • 參考文獻(xiàn):
    1: Kettle JG, Brown S, Crafter C, Davies BR, Dudley P, Fairley G, Faulder P, Fillery S, Greenwood H, Hawkins J, James M, Johnson K, Lane CD, Pass M, Pink JH, Plant H, Cosulich SC. Diverse heterocyclic scaffolds as allosteric inhibitors of AKT. J Med Chem. 2012 Feb 9;55(3):1261-73. doi: 10.1021/jm201394e. Epub 2012 Jan 27. PubMed PMID: 22248236.
  • 溶解性: Soluble  in  DMSO
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 2.912 ml 14.559 ml 29.119 ml
    5 mM 0.582 ml 2.912 ml 5.824 ml
    10 mM 0.291 ml 1.456 ml 2.912 ml
    50 mM 0.058 ml 0.291 ml 0.582 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號(hào):

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:


質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)


  • =
    *
    *


源葉所有產(chǎn)品僅用作科學(xué)研究,銷售產(chǎn)品行為均適用于我司網(wǎng)上所列通用銷售條款。
点击收缩